###begin article-title 0
###xml 13 19 13 19 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHMP2B</italic>
Mutations in CHMP2B in Lower Motor Neuron Predominant Amyotrophic Lateral Sclerosis (ALS)
###end article-title 0
###begin p 1
Conceived and designed the experiments: LEC EFG PRH AH HM SBW AG PGI JK PJS. Performed the experiments: LEC LF EFG PRH AH HM JAH JK. Analyzed the data: LEC LF EFG PRH AH HM SBW AG PGI JK PJS. Contributed reagents/materials/analysis tools: LEC LF EFG PRH AH HM HCH JAH AB KM SBW AG PGI JK PJS. Wrote the paper: LEC LF PRH AH HM AG PGI JK PJS. Provided the clinical data and blood samples for the study: PJS HCH JAH AB CEB KM.
###end p 1
###begin title 2
Background
###end title 2
###begin p 3
###xml 170 176 170 176 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHMP2B</italic>
###xml 390 396 390 396 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHMP2B</italic>
###xml 466 472 466 472 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHMP2B</italic>
###xml 146 154 <span type="species:ncbi:9606">patients</span>
###xml 279 287 <span type="species:ncbi:9606">patients</span>
Amyotrophic lateral sclerosis (ALS), a common late-onset neurodegenerative disease, is associated with fronto-temporal dementia (FTD) in 3-10% of patients. A mutation in CHMP2B was recently identified in a Danish pedigree with autosomal dominant FTD. Subsequently, two unrelated patients with familial ALS, one of whom also showed features of FTD, were shown to carry missense mutations in CHMP2B. The initial aim of this study was to determine whether mutations in CHMP2B contribute more broadly to ALS pathogenesis.
###end p 3
###begin title 4
Methodology/Principal Findings
###end title 4
###begin p 5
###xml 14 20 14 20 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHMP2B</italic>
###xml 544 550 544 550 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHMP2B</italic>
###xml 957 963 957 963 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHMP2B</italic>
Sequencing of CHMP2B in 433 ALS cases from the North of England identified 4 cases carrying 3 missense mutations, including one novel mutation, p.Thr104Asn, none of which were present in 500 neurologically normal controls. Analysis of clinical and neuropathological data of these 4 cases showed a phenotype consistent with the lower motor neuron predominant (progressive muscular atrophy (PMA)) variant of ALS. Only one had a recognised family history of ALS and none had clinically apparent dementia. Microarray analysis of motor neurons from CHMP2B cases, compared to controls, showed a distinct gene expression signature with significant differential expression predicting disassembly of cell structure; increased calcium concentration in the ER lumen; decrease in the availability of ATP; down-regulation of the classical and p38 MAPK signalling pathways, reduction in autophagy initiation and a global repression of translation. Transfection of mutant CHMP2B into HEK-293 and COS-7 cells resulted in the formation of large cytoplasmic vacuoles, aberrant lysosomal localisation demonstrated by CD63 staining and impairment of autophagy indicated by increased levels of LC3-II protein. These changes were absent in control cells transfected with wild-type CHMP2B.
###end p 5
###begin title 6
Conclusions/Significance
###end title 6
###begin p 7
###xml 72 78 72 78 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHMP2B</italic>
We conclude that in a population drawn from North of England pathogenic CHMP2B mutations are found in approximately 1% of cases of ALS and 10% of those with lower motor neuron predominant ALS.
###end p 7
###begin p 8
We provide a body of evidence indicating the likely pathogenicity of the reported gene alterations. However, absolute confirmation of pathogenicity requires further evidence, including documentation of familial transmission in ALS pedigrees which might be most fruitfully explored in cases with a LMN predominant phenotype.
###end p 8
###begin title 9
Introduction
###end title 9
###begin p 10
###xml 270 273 270 273 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009872-Shaw1">[1]</xref>
###xml 876 880 876 880 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SOD1</italic>
###xml 882 910 882 910 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Cu/Zn superoxide dismutase 1</italic>
###xml 912 915 912 915 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009872-Siddique1">[2]</xref>
###xml 963 969 963 969 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHMP2B</italic>
###xml 1113 1116 1113 1116 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009872-Parkinson1">[3]</xref>
###xml 1118 1124 1118 1124 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHMP2B</italic>
###xml 1427 1430 1427 1430 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009872-Skibinski1">[4]</xref>
###xml 1650 1653 1650 1653 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009872-Babst1">[5]</xref>
###xml 1670 1674 1670 1674 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VPS2</italic>
###xml 1881 1884 1881 1884 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009872-Babst1">[5]</xref>
###xml 1886 1889 1886 1889 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009872-Babst2">[6]</xref>
###xml 1891 1894 1891 1894 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009872-Katzmann1">[7]</xref>
###xml 1940 1944 1940 1944 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ALS2</italic>
###xml 1949 1953 1949 1953 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ALS8</italic>
###xml 2083 2086 2083 2086 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009872-Hadano1">[8]</xref>
###xml 2088 2091 2088 2091 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009872-Hadano2">[9]</xref>
###xml 2093 2097 2093 2097 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009872-Kunita1">[10]</xref>
###xml 2099 2103 2099 2103 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009872-Nishimura1">[11]</xref>
###xml 1164 1169 <span type="species:ncbi:9606">human</span>
###xml 1282 1287 <span type="species:ncbi:4932">yeast</span>
###xml 1678 1683 <span type="species:ncbi:4932">yeast</span>
Amyotrophic lateral sclerosis (ALS) is a late-onset, relentlessly progressive and eventually fatal neurodegenerative disorder characterised by the injury and death of upper motor neurons (UMN) in the cortex and lower motor neurons (LMN) in the brainstem and spinal cord [1]. The disorder comprises a range of clinical phenotypes depending on the pathoanatomical distribution of the motor system degeneration. Classical ALS is a combined UMN and LMN disorder. The pure LMN disorder of progressive muscular atrophy (PMA) and the pure UMN disorder of primary lateral sclerosis (PLS) share common molecular pathology hallmarks with ALS, and are considered syndromic variants. The majority of ALS cases are sporadic, although 5-10% of cases are familial. Fifteen loci are known to be associated with ALS, and eight causative genes have been identified, the most common of which is SOD1 (Cu/Zn superoxide dismutase 1) [2]. Recently, we identified missense mutations in CHMP2B (charged multivesicular protein 2B) in two individuals with familial ALS, one of whom had associated features of frontotemporal dementia (FTD) [3]. CHMP2B is expressed in all major areas of the human brain, as well as multiple other tissues outside the CNS. Although the exact function of CHMP2B is unknown, its yeast orthologue, vacuolar protein sorting 2 (VPS2), is a component of the ESCRTIII complex (endosomal secretory complex required for transport) [4]. ESCRTIII is an important component of the multivesicular bodies (MVBs) sorting pathway, which plays a critical role in the trafficking of proteins between the plasma membrane, trans-Golgi network and vacuoles/lysosome [5]. Alterations to VPS2 in yeast results in the formation of dysmorphic hybrid vacuole-endosome structures; additionally, disruption to other ESCRTIII components abolishes the ability of MVBs to internalise membrane-bound cargoes [5], [6], [7]. Interestingly, two other MND-causing genes, ALS2 and ALS8, are proposed to contribute to motor neuron injury by causing disruption to the processes of endocytosis and vesicle trafficking [8], [9], [10], [11].
###end p 10
###begin p 11
###xml 11 17 11 17 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHMP2B</italic>
###xml 92 95 92 95 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009872-Skibinski1">[4]</xref>
###xml 171 177 171 177 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHMP2B</italic>
###xml 312 319 312 319 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Intron5</sup>
###xml 306 319 306 319 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHMP2B<sup>Intron5</sup></italic>
###xml 383 390 383 386 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#916;10</sup>
###xml 377 390 377 386 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHMP2B<sup>&#916;10</sup></italic>
###xml 503 506 499 502 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009872-Skibinski1">[4]</xref>
###xml 544 551 540 547 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Intron5</sup>
###xml 538 551 534 547 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHMP2B<sup>Intron5</sup></italic>
###xml 627 631 623 627 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009872-Lee1">[12]</xref>
###xml 774 778 770 774 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009872-Lee1">[12]</xref>
###xml 780 784 776 780 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009872-Filimonenko1">[13]</xref>
Defects in CHMP2B were originally reported in a Danish pedigree with autosomal dominant FTD [4]. The G>C single nucleotide change in the acceptor splice site of exon 6 of CHMP2B affected mRNA splicing, resulting in two aberrant transcripts: inclusion of the 201-bp intronic sequence between exons 5 and 6 (CHMP2BIntron5), or a short deletion of 10bp from the 5' end of exon 6 (CHMP2BDelta10). Expression of mutant CHMP2B protein in cells resulted in aberrant structures dispersed throughout the cytosol [4], and the ectopic expression of CHMP2BIntron5 in cortical neurons caused dendritic retraction prior to neurodegeneration [12]. In addition, autophagosome accumulation and the inhibition of autophagy have been seen in cells expressing the CHMP2B mutations found in FTD [12], [13].
###end p 11
###begin p 12
###xml 165 171 165 171 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al.</italic>
###xml 171 175 171 175 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009872-MartinezVicente1">[14]</xref>
###xml 332 336 332 336 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009872-Neumann1">[15]</xref>
###xml 521 525 521 525 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PGRN</italic>
###xml 628 632 628 632 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009872-Arai1">[16]</xref>
###xml 634 638 634 638 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009872-Baker1">[17]</xref>
###xml 673 679 673 679 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHMP2B</italic>
###xml 894 900 894 900 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHMP2B</italic>
###xml 1135 1141 1135 1141 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHMP2B</italic>
###xml 1490 1496 1490 1496 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHMP2B</italic>
###xml 1601 1607 1601 1607 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHMP2B</italic>
###xml 1624 1632 1624 1632 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 1657 1663 1657 1663 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHMP2B</italic>
###xml 619 627 <span type="species:ncbi:9606">patients</span>
Several neurodegenerative diseases are now believed to contain an element of dysregulation of the lysosomal degradation of proteins, as reviewed by Martinez-Vicente et al.[14]. The results from these recent studies are part of a growing body of evidence that common pathways are involved in a spectrum of neurodegenerative diseases [15]. It was recently discovered that the ubiquitin positive inclusions seen in FTD and ALS contain the same protein, TAR DNA-binding protein-43 (TDP43), and that mutations in progranulin (PGRN) give rise to FTD with ubiquitin-positive inclusion bodies similar to those seen in some ALS patients [16], [17]. It is proposed that mutations in CHMP2B may lead to FTD and other neurodegenerative diseases, including ALS, which is predicted to involve disruption to the cellular processes involved in the recycling and degradation of proteins. However, the status of CHMP2B mutations as a contributor to ALS has remained uncertain, due to the lack of described pedigrees where mutations segregate with disease in multiple affected individuals. The aims of this study were i) to identify whether mutations in CHMP2B contribute significantly to the pathogenesis of familial and apparently sporadic ALS, by screening for genetic alterations in a cohort of 433 ALS cases in whom the clinical phenotype had been documented serially throughout the disease course; ii) to investigate in CNS tissue changes in the gene expression profile of motor neurons from cases with CHMP2B mutations compared to neurologically normal controls, and iii) to investigate the functional effects of CHMP2B mutations in an in vitro system. We propose that CHMP2B missense mutations associate with ALS and demonstrate that these mutations give rise to a distinct clinical and neuropathological phenotype, cause a distinctive alteration in the motor neuron transcriptome and disrupt cellular pathology, compared to controls.
###end p 12
###begin title 13
Methods
###end title 13
###begin title 14
###xml 0 8 <span type="species:ncbi:9606">Patients</span>
Patients and controls
###end title 14
###begin p 15
###xml 117 121 117 121 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SOD1</italic>
###xml 123 128 123 128 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TDP43</italic>
###xml 130 137 130 137 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FUS/TLS</italic>
###xml 139 142 139 142 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ANG</italic>
###xml 147 151 147 151 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VAPB</italic>
###xml 376 384 <span type="species:ncbi:9606">patients</span>
DNA samples from 433 ALS cases were screened. Of these 37 had familial ALS (FALS) and were negative for mutations in SOD1, TDP43, FUS/TLS, ANG and VAPB; 356 had classical sporadic ALS with UMN and LMN clinical signs and 40 had ALS with a LMN phenotype throughout the disease course (PMA variant). Autopsy CNS tissue was available for 123 of the cases screened and for all the patients in whom a mutation in CHMP2B was found. DNA control samples (N = 500) were obtained from the Sheffield and Birmingham MND DNA banks and the Newcastle Brain Tissue Resource. All control individuals were neurologically normal and matched to the disease cohort by age and sex. Approval for the use of DNA samples was obtained from the South Sheffield Research Ethics Committee and written consent was obtained from the donors. Ethnicity of cases and controls was UK Caucasian.
###end p 15
###begin title 16
PCR amplification and mutation screening of CHMP2B
###end title 16
###begin p 17
###xml 79 83 79 83 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009872-Brockington1">[18]</xref>
###xml 132 138 132 138 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHMP2B</italic>
###xml 151 154 151 154 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009872-Skibinski1">[4]</xref>
###xml 255 259 255 259 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009872-Brockington1">[18]</xref>
###xml 265 271 265 271 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHMP2B</italic>
###xml 485 490 <span type="species:ncbi:9606">Human</span>
DNA was extracted from snap frozen cerebellum or blood as described previously [18]. PCR was performed as described in the original CHMP2B publication [4]. Following clean-up with ExoSAP-IT (GE Healthcare, UK), PCR products were bidirectionally sequenced [18]. The CHMP2B nucleotide sequence was taken from ENST00000263780 on the Ensembl database, and was used to determine sites of known polymorphisms. Nucleotides were numbered in accordance with the nomenclature recommended by the Human Genome Variation Society ().
###end p 17
###begin p 18
###xml 140 143 140 143 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Acc</italic>
###xml 382 385 382 385 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ban</italic>
To determine the prevalence of the c.311C>A change in the control population, exon 3 PCR products were digested with the restriction enzyme AccI, generating 244, 104 & 51bp fragments from the wild type sequence. The C to A substitution abolishes a restriction site, resulting in two fragments (244 & 155bp). The c.618A>C change was screened by digestion of exon 6 PCR products with BanI, which generated 207 & 96bp in the presence of the substitution, whilst the wild type sequence of 303bp remained uncut. The presence of c.-151C>A and c.85A>G in the control population were determined by bidirectional sequencing of exons 1 and 2, respectively.
###end p 18
###begin title 19
Neuropathology
###end title 19
###begin p 20
###xml 616 623 612 619 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0009872-t001">Table 1</xref>
Brains and spinal cords were dissected so that one cerebral hemisphere, the midbrain, left hemi-brainstem and left cerebellar hemisphere were sliced for snap freezing. Selected spinal cord segments were also snap frozen. The remaining tissues were fixed in formalin for processing to paraffin wax and used in routine staining and immunocytochemistry from all CNS levels. Standard immunocytochemical methods, including antigen retrieval where appropriate, were used to demonstrate localization of ubiquitin, p62/sequestosome 1, TDP43, CD68 (a marker of microglial activation), alpha-synuclein and AT8 (a tau marker) (Table 1). The pathological survey reported here includes examination of cervical and lumbar limb enlargements of the spinal cord, thoracic spinal cord, multiple medulla oblongata and pontine levels to include lower cranial motor nerve nuclei, upper pons and midbrain, the hippocampus, motor cortex, frontal and temporal neocortex and cerebellum.
###end p 20
###begin title 21
Antibody source and conditions.
###end title 21
###begin title 22
Microarray analysis of cervical motor neurons from CHMP2B cases vs. controls
###end title 22
###begin p 23
###xml 319 323 319 323 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009872-Ferraiuolo1">[19]</xref>
###xml 567 571 567 571 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009872-VanGelder1">[20]</xref>
###xml 726 732 726 732 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHMP2B</italic>
###xml 1185 1191 1185 1191 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHMP2B</italic>
###xml 1365 1371 1365 1371 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHMP2B</italic>
###xml 1428 1429 1428 1429 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">t</italic>
###xml 1808 1814 1808 1814 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHMP2B</italic>
###xml 1940 1944 1940 1944 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009872-Dennis1">[21]</xref>
###xml 808 813 <span type="species:ncbi:9606">Human</span>
Snap frozen cervical spinal cord was available for cases 1-3, but not case 4, and the cervical cord from 7 control cases was used for comparison. Ten micron sections were prepared, and 500 motor neurons were isolated from each sample using laser-capture microdissection (LCM); RNA was extracted as previously described [19]. The quality (2100 bioanalyzer, RNA 6000 Pico LabChip; Agilent, CA, USA) and quantity (NanoDrop 1000 spectrophotometer) of the RNA from all of the samples were assessed. Each RNA sample was linearly amplified, following the Eberwine procedure [20] using the Two-cycle Amplification Method (Affymetrix), and again checked for quality and quantity. Fifteen micrograms of amplified cRNA from the 3 mutant CHMP2B cases and 7 controls was fragmented and each hybridised individually to 10 Human Genome U133 Plus 2.0 GeneChips (Affymetrix), as per manufacturer's protocols. Following stringency washes, chips were stained and scanned, and GeneChip Operating Software (GCOS) used to produce signal intensities for each transcript. ArrayAssist (Iobion Informatics, CA, USA) was used to determine genes that showed significant differential expression in the presence of CHMP2B mutations compared to control samples. Transcripts were considered differentially expressed if there was a twofold or greater difference in the mean signal intensity of the CHMP2B cases compared to the control group (p<0.05, two-tailed t test). Transcripts in which the signal intensities on all 10 GeneChips were below 35 (the average intensity of background noise level) were discarded as were those transcripts of unknown function. The differentially expressed transcripts on the resulting list were classified by biological process, as determined by GeneOntology terms. To identify specific pathways affected by CHMP2B mutations, PathwayArchitect (Stratagene) and the DAVID Functional Annotation Tool bioinformatics software packages were used [21].
###end p 23
###begin title 24
Validation of microarray results by Q-PCR
###end title 24
###begin p 25
###xml 134 140 134 140 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHMP2B</italic>
###xml 152 159 152 159 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0009872-t002">Table 2</xref>
###xml 506 510 502 506 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009872-Ferraiuolo1">[19]</xref>
###xml 611 615 607 611 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009872-Livak1">[22]</xref>
###xml 740 741 736 737 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">t</italic>
Primers were designed and optimised to validate significant changes in expression of genes with key roles in the pathways affected by CHMP2B mutations (Table 2). Q-PCR was perfomed using 25ng of cDNA, 1x Brilliant II SYBR Green QPCR Master Mix (Agilent, CA, USA), the optimised concentrations of forward and reverse primers, and nuclease free water was used to make a final reaction volume of 20microl. Samples were run on an Mx3000P Real-Time PCR system (Stratagene) using previously published parameters [19]. Gene expression values, normalised to actin expression, were determined using the ddCt calculation [22]. Actin was selected as a housekeeping gene as its expression was consistent across the 10 GeneChips. An unpaired two-tailed t test was used to analyse the data and to determine the statistical significance of any differences in gene expression (GraphPad Prism 5, Hearne Scientific Software).
###end p 25
###begin title 26
Primer sequences for Q-PCR validation of selected genes.
###end title 26
###begin title 27
###xml 0 8 0 8 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">In vitro</italic>
In vitro models to investigate the functional effects of CHMP2B mutations
###end title 27
###begin p 28
###xml 278 284 278 284 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHMP2B</italic>
###xml 1770 1771 1746 1747 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 163 167 <span type="species:ncbi:9913">calf</span>
###xml 990 994 <span type="species:ncbi:9925">goat</span>
###xml 1054 1059 <span type="species:ncbi:10090">mouse</span>
###xml 1136 1142 <span type="species:ncbi:9986">rabbit</span>
###xml 1146 1151 <span type="species:ncbi:10090">mouse</span>
###xml 1202 1207 <span type="species:ncbi:10090">mouse</span>
###xml 1217 1223 <span type="species:ncbi:9986">rabbit</span>
###xml 1248 1253 <span type="species:ncbi:10090">mouse</span>
###xml 1263 1269 <span type="species:ncbi:9986">rabbit</span>
HEK-293 cells (ECACC) were plated on 13mm coverslips in Dulbecco's Modified Eagle's Medium ((DMEM) w Glucose + L-glutamine, w/o Na pyruvate; Lonza) plus 10% fetal calf serum (FCS, Biosera), in the absence of antibiotic (termed +/-). Cells were transfected with 500ng myc-tagged CHMP2B with either the wild-type, c.85A>G (p.I29V), c.311C>A (p.T104N) or c.618A>C (p.Q206H) sequence, under a constitutive cytomegalovirus promoter, using Lipofectamine 2000 (Invitrogen) as per the manufacturer's protocol. After transfection, cells were grown in DMEM plus 10% FCS for 24 hours. To investigate changes in the lysosomal degradation pathway, autophagy was induced in selected cells by serum withdrawal for two hours, 22 hours post-transfection. Cells are subsequently referred to as +/- (10% FCS, no antibiotic) or -/- (no FCS for the last 2 hours of growth post-transfection, no antibiotic). Cells were fixed, (4% paraformaldehyde (Sigma)), permeabilised (0.1% triton (Sigma)), and blocked in 5% goat serum (Sigma) in PBS for one hour. Primary antibodies were mouse alpha-CD63 (in-house), a marker of late-endosomes and lysosomes, and either rabbit or mouse alpha-myc (AbCam). Secondary antibodies were anti-mouse or alpha-rabbit AlexaFluor488 and alpha-mouse or alpha-rabbit AlexaFluor555 (Molecular Probes). Cells were visualised using the Zeiss Axioplan2 microscope and the Zeiss LSM 510 confocal microscope. Transfected cells were scored for the presence of vacuoles and halos. To measure vacuole area, images were captured from a minimum of 25 fields of view per transfection round. ImageJ was used to convert the images to greyscale, subtract the background and adjust the threshold. The 'analyse particles' plug-in was used to measure the area of the vacuoles in microm2.
###end p 28
###begin p 29
###xml 566 567 558 559 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">g</italic>
###xml 1246 1252 <span type="species:ncbi:9986">rabbit</span>
###xml 1303 1309 <span type="species:ncbi:9986">rabbit</span>
COS-7 cells (ECACC) were plated in 6 well tissue culture plates in DMEM, plus 10% FCS, in the absence of antibiotic 24 hours prior to transfection (DMEM+/-). Cells were transfected with 2microg of plasmid DNA, as described above, using Lipofectamine 2000 as per the manufacturer's protocol. To induce autophagy, 22 hours post-transfection cells were serum starved for 2 hours, before being washed in PBS and collected in 500microl 1x Trypsin-EDTA (TE). An equal volume of DMEM+/- was added to the cells to quench the TE, and cells were pelleted by spinning at 3,000xg for 2 minutes. Cells were washed with 500microl PBS and spun again to re-pellet. The supernatant was discarded and cells were resuspended in 40microl of lysis buffer (25microM Tris pH7.4, 0.5% (v/v) Triton, 50mM NaCl, 2mM EDTA, plus protease inhibitor cocktail) and lysed at 4degreesC. Protein concentration was estimated using a Bradford assay, and 20microg of total protein per sample was separated by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) (12% acrylamide gels) and transferred to PVDF membranes. Blots were blocked in TBS-T (20mM Tris-HCl pH7.6, 137mM NaCl, plus 0.1% (v/v) Tween-20) and 5% (w/v) dried skimmed milk. They were then probed with rabbit polyclonal anti-LC3 (Stratech) diluted 1:1000 and rabbit polyclonal anti-actin diluted 1:1000 (used as a protein loading control) in TBS-T plus milk for one hour at room temperature, followed by peroxidase-conjugated secondary antibody (1:4000, one hour at room temperature). Antibody binding was revealed using enhanced chemiluminescence, as per the manufacturer's instructions.
###end p 29
###begin title 30
Results
###end title 30
###begin title 31
###xml 36 44 <span type="species:ncbi:9606">patients</span>
Mutation screening of CHMP2B in ALS patients
###end title 31
###begin p 32
###xml 76 82 76 82 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHMP2B</italic>
###xml 151 159 151 159 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0009872-g001">Figure 1</xref>
###xml 614 617 614 617 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009872-Parkinson1">[3]</xref>
###xml 746 755 746 755 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0009872.s002">Figure S1</xref>
###xml 974 977 974 977 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009872-Parkinson1">[3]</xref>
###xml 1039 1045 1039 1045 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHMP2B</italic>
###xml 166 173 <span type="species:ncbi:9606">patient</span>
###xml 520 527 <span type="species:ncbi:9606">patient</span>
###xml 719 726 <span type="species:ncbi:9031">chicken</span>
###xml 731 740 <span type="species:ncbi:7955">zebrafish</span>
Sequence analysis of the entire coding region and intron/exon boundaries of CHMP2B from 433 ALS cases identified point mutations in four cases (0.9%) (Figure 1). One patient (Case 1) was heterozygous for a previously undescribed mutation, a single nucleotide substitution, c.311C>A, which results in the substitution of threonine by asparagine (p.T104N). Two subjects (Cases 2 & 3), were heterozygous for a c.85A>G substitution, resulting in a previously described isoleucine to valine substitution (p.I29V). The fourth patient (Case 4) was the previously published glutamine to histidine (c.618A>C, p.Q206H) case [3]. These mutations are all highly conserved in mammals, with the p.T104N and p.Q206H also conserved in chicken and zebrafish (see Figure S1). The c.311C>A, c.85A>G and c.618A>C changes were absent in 1000 control chromosomes from 500 neurologically normal individuals. The c.618A>C mutation has previously been shown to be absent in 1280 control chromosomes [3]. A novel SNP, c.-151C>A, was also identified in the 5'UTR of CHMP2B in four cases (0.9%), however, this change was also present in 2% of controls.
###end p 32
###begin title 33
###xml 44 50 44 50 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHMP2B</italic>
Chromatograms showing nucleotide changes in CHMP2B.
###end title 33
###begin p 34
###xml 153 159 153 159 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHMP2B</italic>
On the left side of each image is the normal wild-type sequence, whilst the right side shows the nucleotide change for each of the changes identified in CHMP2B.
###end p 34
###begin title 35
###xml 23 31 <span type="species:ncbi:9606">patients</span>
Clinical phenotypes of patients carrying mutations in CHMP2B
###end title 35
###begin p 36
In all cases neurological investigations including haematological and biochemical blood tests, CSF analysis, neuroimaging and neurophysiological evaluation were compatible with a diagnosis of ALS. None of the cases presented with or developed signs of frontotemporal dementia (FTD).
###end p 36
###begin p 37
###xml 25 28 <span type="species:ncbi:9606">man</span>
Case 1 was a 54 year old man who presented with respiratory failure and bulbar dysfunction. His first problem was dyspnoea whilst swimming. He was treated with non-invasive ventilation (NIV) from the time of diagnosis throughout his illness. There was no reported family history of neurological disease. On examination at the time of presentation, he had a moderately severe dysarthria and bilateral wasting, fasciculation and weakness of the tongue. He had wasting and proximal fasciculation in the upper and lower limbs, weakness of the ulnar and median innervated intrinsic hand muscles and the hip flexors. The deep tendon reflexes were normal and plantar responses were flexor, consistent with a pure lower motor neuron phenotype. His symptoms progressed rapidly over the course of 15 months, at which stage he died of respiratory failure with relatively preserved limb function.
###end p 37
###begin p 38
Case 2 was a 64 year old female who presented with back pain and progressive weakness of the right leg. She underwent L4/5 spinal decompression to no avail and her symptoms continued to progress to affect both legs, with later development of upper limb, bulbar and respiratory muscle weakness. There was no significant family history. On examination she had wasting and predominantly distal weakness in the lower limbs with upper limb fasciculations. The reflexes were normal throughout, and the plantar reflexes were flexor. She died 66 months after symptom onset.
###end p 38
###begin p 39
###xml 25 28 <span type="species:ncbi:9606">man</span>
Case 3 was a 49 year old man who initially noticed a deterioration in his ability to play football, due to weakness affecting his left leg. His symptoms progressed steadily. Fifteen months after onset he had wasting and fasciculations in the upper limbs with preserved power. The lower limbs were wasted globally, most severely in the left anterior tibial compartment. Power in hip flexion and ankle dorsiflexion was reduced on the left and the ankle jerks were absent bilaterally. He developed bulbar symptoms 24 months after disease onset. No UMN signs were detectable clinically throughout the disease course. There was no family history of ALS, with healthy parents and 5 siblings, including one with developmental delay described as possible autism. He died of respiratory failure 29 months after his initial symptom onset.
###end p 39
###begin p 40
Case 4 was a 73 year old male who presented with dysarthria, dysphagia and clumsiness of the hands. His symptoms progressed rapidly and 12 months after onset he had a wasted, fasciculating tongue, LMN weakness in the upper and lower limbs, depressed reflexes and flexor plantar responses. He died 14 months after disease onset. He had a cousin who had died from ALS several years earlier.
###end p 40
###begin title 41
Neuropathological findings in the four cases with CHMP2B mutations
###end title 41
###begin p 42
###xml 153 161 153 161 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0009872-g002">Figure 2</xref>
###xml 377 386 377 386 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0009872-g002">Figure 2a</xref>
###xml 643 647 643 647 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009872-Ince1">[23]</xref>
###xml 1154 1157 1154 1157 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009872-Parkinson1">[3]</xref>
###xml 1280 1286 1280 1286 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHMP2B</italic>
###xml 1322 1325 1322 1325 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009872-Parkinson1">[3]</xref>
###xml 1435 1439 1435 1439 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009872-Mackenzie1">[24]</xref>
The anatomical and molecular pathology of all four cases was similar and corresponded to a rather stereotypical pattern of LMN predominant degeneration (Figure 2). Involvement of UMNs was not detectable in conventional stains and the Betz cell somata were readily identified and appeared normal in all cases. There was no evidence of myelin pallor in the corticospinal tracts (Figure 2a) other than equivocal changes in the medullary pyramid of one case (Case 1), which was not present in the spinal cord at any level. Microglial activation demonstrated by CD68 staining is a more sensitive indication of early white matter tract degeneration [23]. Three of the cases showed no evidence for corticospinal tract degeneration at any level. One case (Case 1) showed marked subcortical microglial activation centred on the precentral gyrus, mild changes in the medulla and only equivocal changes in the spinal cord white matter. Glial pathology was previously reported in the motor cortex in case 4, comprising oligodendroglial coiled bodies immunoreactive for p62 and TDP43, which were not readily demonstrated by conventional ubiquitin immunocytochemistry [3]. These lesions were present in the motor cortex and the ventral horns of all the cases. These lesions are not confined to CHMP2B-related ALS as previously reported [3], but are consistently present to a variable degree in sporadic and non-SOD1-related familial variants of ALS [24].
###end p 42
###begin title 43
Photomicrography of pathological changes associated with CHMP2B mutations.
###end title 43
###begin p 44
###xml 88 89 88 89 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">a</bold>
###xml 199 200 199 200 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">b</bold>
###xml 236 237 236 237 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">c</bold>
###xml 365 366 365 366 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">d</bold>
###xml 449 450 449 450 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">e</bold>
###xml 461 462 461 462 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">f</bold>
###xml 551 554 551 554 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">g&#8211;i</bold>
In all cases there was no evidence of myelin pallor affecting the corticospinal tracts (a). Case 1 showed some minor upregulation of CD68 immunoreactivity in the spinal lateral corticospinal tracts (b) compared with the dorsal columns (c). Sequestosome 1/p62 staining showed compact intraneuronal inclusions in spinal motor neurons and occasional glial inclusions (d). The glial inclusions show coiled body morphology immunoreactive for both TDP43 (e) and p62 (f). All cases showed a predominance of compact intraneuronal inclusions in motor neurons (g-i). (a: Luxol fast blue; b,c: CD68; d,f,h,i: p62; e,g: TDP43. Microscopy at x2 obj. (a); x10 obj. (b,c); x40 obj. (d-i)).
###end p 44
###begin p 45
###xml 439 456 439 456 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0009872-g002">Figures 2d,g,h, i</xref>
The LMN pathology in all cases was typical of the primary muscular atrophy (PMA) variant of ALS. There was variable severe loss of motor neurons from all spinal levels. Bulbar motor nuclei were generally less severely affected. Surviving motor neurons contained a population of inclusion bodies demonstrated by ubiquitin, p62 and TDP43 staining. In three cases these were exclusively of 'compact' morphology with no demonstrable 'skeins' (Figures 2d,g,h, i). All the glia and neurones containing TDP43 intracytoplasmic inclusions showed decreased staining in the cell nucleus in comparison to retention of normal nuclear staining in cells negative for inclusions. One case showed very few intraneuronal lesions, in the context of massive motor neuronal loss, of rather indeterminate morphology. Bunina bodies were absent from all the cases. Extramotor involvement of the CNS assessed by p62/TDP43 immunoreactive lesions was absent including evaluation of the hippocampal dentate granule cells and the frontal and temporal neocortex. Staining for related neurodegenerative pathologies (tau and alpha-synuclein) showed minimal expression of Alzheimer's disease pathology (low Braak stage and minimal cortical amyloid deposition) and absence of synucleinopathy.
###end p 45
###begin title 46
Gene expression profiling of motor neurons from CHMP2B cases compared to controls
###end title 46
###begin p 47
###xml 113 119 113 119 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHMP2B</italic>
###xml 837 844 833 840 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0009872-t003">Table 3</xref>
###xml 870 878 866 874 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0009872.s001">Table S1</xref>
The percentage of genes described as present on the 10 GeneChips was an average of 22.7% for the three available CHMP2B cases (2x p.I29V, 1x p.T104N), and 28.2% for the seven neurologically normal control cases. (CEL files for each of the 10 GeneChips have been submitted to the Gene Expression Omnibus Repository, Accession GSE19332). ArrayAssist (Affymetrix) was used to analyse expression data. Duplicate probes were removed, as were probes for unknown genes, and those for which the signal intensity in all 10 GeneChips was below 35 (the average background level). After filtering, 890 genes were found to be downregulated, and 555 upregulated, all with a fold change >/=2, and p value </=0.05. These 1,445 differentially expressed genes were then categorised according to their biological process, as defined by GeneOntology terms (Table 3) (Full list available in Table S1). An additional 398 genes were downregulated and 358 upregulated at a fold change of 1.5-1.99, p</=0.05. These were only considered if they were involved in the pathways of interest.
###end p 47
###begin title 48
Grouping of 891 downregulated and 556 upregulated genes, with a fold change (FC) >/=2, and p value </=0.05, into their biological process, as defined by GeneOntology terms.
###end title 48
###begin p 49
###xml 433 440 433 440 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0009872-t004">Table 4</xref>
The functional annotation tool of the DAVID Bioinformatics Resource was used to identify pathways with a significant number of differentially expressed genes, namely: axon guidance, regulation of actin cytoskeleton and SNARE interactions in vesicular transport, mammalian target of rapamycin (mTOR) signalling and regulation of autophagy, mitogen activated kinase (MAPK) signalling, calcium signalling, and cell cycle and apoptosis (Table 4). We focused our analysis on pathways that were of most biological interest in relation to the predicted function of CHMP2B and related proteins.
###end p 49
###begin title 50
###xml 226 232 226 232 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHMP2B</italic>
Genes altered in calcium signalling, MAPK signalling, axon guidance, cell cycle and apoptosis, regulation of actin cytoskeleton and SNARE interactions in vesicular transport, and mTOR signalling and regulation of autophagy in CHMP2B motor neurons compared to neurologically normal controls.
###end title 50
###begin p 51
(Fold change: positive numbers indicate upregulated, whilst negative numbers depict downregulated transcripts).
###end p 51
###begin title 52
###xml 80 88 80 88 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0009872-g003">Figure 3</xref>
Regulation of actin cytoskeleton and SNARE interactions in vesicular transport (Figure 3)
###end title 52
###begin title 53
Summary of key gene expression changes to ER and Golgi function, vesicular transport, mTOR signalling and autophagy.
###end title 53
###begin p 54
The downregulation of multiple transcripts encoding ribosomal proteins, translation initiation factors (eIFs) and the ribosomal subunit, RPS6 suggests a global repression of translation within the cell (1). SEC23 and SEC24 coat vesicles into which immature proteins are packaged and are upregulated. Vesicles are transported along microtubules (MTs) from the ER-Golgi intermediate compartment; however, downregulation of the main components of microtubules, TUBA and TUBB, and the MT-stabilising proteins, MAP1S and MAP4, indicates MT disassembly and therefore disruption to vesicular transport (2). This is enhanced by upregulation of STMN1, a MT-destabilising protein, whose over-expression has also been demonstrated to result in Golgi fragmentation. Downregulation of transcripts maintaining Golgi structure (GLG1, GORASP1, COG2 and COG7) support the hypothesis of Golgi fragmentation (3). COPI is used to coat empty vesicles exiting the Golgi for recycling back to the ER, however, two main constituents, COPE and COPZ1, are downregulated, as is USE1, which is required for vesicle fusion with the ER. These findings predict an eventual deficit of material available to ER for the packaging of newly synthesised proteins (4). There is dysregulation of multiple SNARE transcripts, which are required for vesicle fusion. BOS1 and SEC22 are upregulated, which may be the Golgi's response to the reduction in vesicles being transported along destabilised microtubules. Multiple SNAREs and adaptor proteins (VTI1, STX4, AP1B1, AP2A2, AP2S1, AP3D1 and AP4B1), which are required for fusion between vesicles carrying mature proteins and the cell surface, endosomes and lysosomes, are downregulated, predicting impairment in the delivery of proteins throughout the cell (5). Finally, inhibition of autophagy by the mTORC1 complex and downregulation of ATG1, which forms the phagophore assembly site (PAS) with ATG17 and ATG13 to initiate autophagy, indicates a decrease in the clearance of cellular debris which may result in cytosolic accumulations and contribute to motor neuron injury (6).
###end p 54
###begin p 55
###xml 35 40 35 40 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MAP1S</italic>
###xml 49 53 49 53 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MAP4</italic>
###xml 103 107 103 107 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009872-Halpain1">[25]</xref>
###xml 244 249 212 217 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">STMN1</italic>
###xml 311 317 268 274 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHMP2B</italic>
###xml 443 448 400 405 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KIF1A</italic>
###xml 469 474 410 415 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KIF5C</italic>
###xml 500 505 425 430 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KIF1C</italic>
###xml 552 559 461 468 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">DYNLRB1</italic>
###xml 582 588 475 481 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">DYNLL2</italic>
###xml 612 619 489 496 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">DYNC1H1</italic>
###xml 744 748 605 609 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TUBA</italic>
###xml 771 775 616 620 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TUBB</italic>
###xml 863 888 692 717 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Golgi apparatus protein 1</italic>
###xml 890 894 719 723 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GLG1</italic>
###xml 1020 1026 833 839 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHMP2B</italic>
###xml 1113 1120 926 933 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GORASP1</italic>
###xml 1199 1203 996 1000 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">COG2</italic>
###xml 1229 1233 1010 1014 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">COG7</italic>
Microtubule-associated protein 1s (MAP1S) and 4 (MAP4), are involved in microtubule (MT) stabilisation [25], and are both downregulated (down double arrow2.8 and down double arrow3, respectively), whereas the MT-destabilising protein stathmin (STMN1), is upregulated (up dbl arrow1.6) in the presence of mutant CHMP2B. Microtubule destabilisation may result in transport impairment, and this is supported by downregulation of several kinesin (KIF1A down double arrow3, KIF5C down double arrow2.8 and KIF1C down double arrow2.2) and dynein transcripts (DYNLRB1 down double arrow2.8, DYNLL2 down double arrow3 and DYNC1H1 down double arrow3.5). In addition, both tubulin alpha and beta, main components of microtubules, are highly downregulated (TUBA down double arrow4.5, TUBB down double arrow5), probably in response to destabilising stimuli. The transcript for Golgi apparatus protein 1 (GLG1), used as a marker to assess Golgi apparatus (GA) structure and function, is highly downregulated (down double arrow3.16) in CHMP2B motor neurons, as are other structural proteins: Golgi reassembly stacking protein 1 (GORASP1 down double arrow3.7) and components of the oligomeric Golgi complex 2 and 7 (COG2 down double arrow1.5 and COG7 down double arrow2.6).
###end p 55
###begin p 56
###xml 112 116 112 116 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BET1</italic>
###xml 167 171 167 171 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">STX5</italic>
###xml 212 217 212 217 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GOSR2</italic>
###xml 240 246 229 235 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SEC22A</italic>
###xml 248 249 237 238 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</italic>
###xml 269 270 247 248 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</italic>
###xml 272 277 250 255 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SEC23</italic>
###xml 282 287 260 265 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SEC24</italic>
###xml 462 466 418 422 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">USE1</italic>
###xml 580 584 536 540 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009872-Dilcher1">[26]</xref>
###xml 691 695 631 635 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">COPE</italic>
###xml 700 705 640 645 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">COPZ1</italic>
###xml 910 914 818 822 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VTI1</italic>
###xml 942 946 834 838 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">STX4</italic>
###xml 1161 1166 1037 1042 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">AP1B1</italic>
###xml 1192 1197 1052 1057 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">AP2A2</italic>
###xml 1223 1228 1067 1072 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">AP2S1</italic>
###xml 1254 1259 1082 1087 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">AP3D1</italic>
###xml 1288 1293 1100 1105 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">AP4B1</italic>
###xml 1422 1427 1218 1223 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KIF1A</italic>
###xml 1429 1433 1225 1229 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TUBB</italic>
###xml 1438 1442 1234 1238 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MAP4</italic>
###xml 1612 1619 1408 1415 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0009872-t005">Table 5</xref>
Fusion of ER-derived vesicles with the Golgi requires the pairing of the v-SNARE, blocked early in transport 1 (BET1), with its t-SNARE complex comprising syntaxin 5 (STX5), Golgi SNAP receptor complex member 2 (GOSR2;up dbl arrow2.76) and SEC22A, B (up dbl arrow1.6), C. SEC23 and SEC24, whose function is to coat the vesicles travelling along microtubules to the cis-Golgi, are also upregulated (up dbl arrow1.5 and up dbl arrow1.8 respectively). In contrast, USE1 (unconventional SNARE in the ER homologue 1), which is involved in retrograde transport from the Golgi to the ER [26], is downregulated (down double arrow2.66). Furthermore, two components of the coatomer protein complex I, COPE and COPZ1 are downregulated (down double arrow3.8 and down double arrow3 respectively). This complex is responsible for coating of the vesicles travelling between ER and Golgi. Also downregulated are the t-SNAREs, VTI1 (down double arrow2.9) and STX4 (down double arrow2.2), which encode proteins involved in vesicle docking and transport from the GA to the endosome. In addition, many of the adaptor-related protein complex transcripts are strongly downregulated, AP1B1 (down double arrow2.29), AP2A2 (down double arrow2.25), AP2S1 (down double arrow3.35), AP3D1 (down double arrow2.67) and AP4B1 (down double arrow2), and these also play a key role in the transport of vesicles from the GA to the endosomal sorting pathway. KIF1A, TUBB and MAP4 were selected for verification by Q-PCR and were found to be significantly downregulated by 2.96 (p = 0.0009), 3.07 (p<0.0001) and 3.52 fold (p = 0.0003), respectively (Table 5).
###end p 56
###begin title 57
Comparison of fold-changes calculated by microarray experiments and determined by Q-PCR.
###end title 57
###begin p 58
###xml 59 60 59 60 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">t</italic>
The p value for the Q-PCR was calculated using an unpaired t test.
###end p 58
###begin title 59
###xml 45 53 45 53 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0009872-g003">Figure 3</xref>
mTOR signalling and regulation of autophagy (Figure 3)
###end title 59
###begin p 60
###xml 221 225 221 225 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009872-Hay1">[27]</xref>
###xml 227 231 227 231 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009872-Fang1">[28]</xref>
###xml 339 343 336 340 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009872-Kim1">[29]</xref>
###xml 639 643 620 624 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009872-Cheong1">[30]</xref>
###xml 835 839 816 820 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PP2A</italic>
###xml 942 946 907 911 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PP2A</italic>
###xml 1047 1051 1012 1016 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009872-Holz1">[31]</xref>
###xml 1155 1159 1120 1124 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009872-Holz1">[31]</xref>
###xml 1391 1395 1260 1264 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009872-Miyamoto1">[32]</xref>
###xml 1531 1535 1384 1388 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009872-Lekmine1">[33]</xref>
###xml 1837 1841 1658 1662 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009872-Shahbazian1">[34]</xref>
###xml 1843 1847 1664 1668 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ATG1</italic>
###xml 1928 1935 1749 1756 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0009872-t005">Table 5</xref>
mTOR is a serine/threonine protein kinase that integrates the input from multiple upstream pathways, and whose activity is stimulated by insulin, growth factors, serum, phosphatidic acid, amino acids and oxidative stress [27], [28]. mTOR associates with several other proteins: Raptor, GbetaL and PRAS40, to form a complex known as mTORC1 [29]. mTOR is involved in many cellular processes, one of which is the inhibition of autophagy. Importantly, a key protein involved in autophagy activation, ATG1, is strongly downregulated (down double arrow3.48). ATG1 is essential for the formation of vesicles at the phagophore assembly site (PAS) [30], suggesting autophagy is impaired in CHMP2B motor neurons. In addition to its role in autophagy inhibition, the mTOR signalling pathway is involved in translation initiation. mTORC1 inhibits PP2A (protein phosphatase 2A), of which the regulatory subunit 4 is downregulated (down double arrow2.03). PP2A inhibits p70S6K, which binds to the eukaryotic translation initiation factor 3 (eIF3) when inactive [31]. Activation of p70S6K by mTORC1 causes it to release eIF3, allowing p70S6K to activate target proteins [31]. eIF3 consists of twelve non-identical subunits (eIF3 A(down double arrow2.03), B(down double arrow3.97), C(3.23down double arrow), D(down double arrow2.28), E, F, G(down double arrow1.80), H, I(down double arrow5.79), J, K and L) [32]. Upon release from p70S6K, eIF3 binds to ribosomal protein S6 (RPS6, down double arrow2.28), which is part of the 40S ribosome subunit [33]. The eIF3/40S complex then forms a larger pre-initiation complex with eIF4E, eIF4G, eIF4B (down double arrow1.94) and eIFA (down double arrow3.04). eIF4A plays a role in resolving 5'UTR mRNA secondary structure, and thus allowing the ribosome to bind, and this helicase action is facilitated by eIF4B [34]. ATG1 was selected for Q-PCR verification, and was downregulated 2.2 fold, p = 0.003 (Table 5).
###end p 60
###begin title 61
###xml 17 25 17 25 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0009872-g004">Figure 4</xref>
MAPK signalling (Figure 4)
###end title 61
###begin title 62
###xml 55 61 55 61 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHMP2B</italic>
Defects in MAPK signalling as a result of mutations in CHMP2B.
###end title 62
###begin p 63
There are two main pathways through which MAP kinases signal: the classical MAPK pathway and the p38 MAP kinase pathway. In the classical signalling pathway, ligand binding results in receptor activation, which in turns leads to the activation of GRB2 and SOS. SOS catalyses the substitution of GDP for GTP on RAS (down double arrow), which then activates RAF1 (down double arrow). RAF1 subsequently phosphorylates MEK1/2, which in turn activate ERK1 and ERK2 (down double arrow). The ERK proteins activate MKNK2 (down double arrow), which is directly responsible for activation of proteins required for translation initiation. Downregulation of multiple core signalling components in combination with upregulation of the inhibitors, NF1 and PTPN5 predicts inability of the cell's basal response to growth factors. The p38 MAPK pathway is a signalling cascade that is distinct, but not exclusive from the classical MAPK signalling pathway. As with the classical MAPK pathway, multiple elements of the pathway are downregulated: TAK1(down double arrow), p38 (down double arrow), MK2 (down double arrow) and HSP27 (down double arrow) which may result in a decrease in mRNA stability and the cell's anti-apoptotic response. (PM = plasma membrane)
###end p 63
###begin p 64
###xml 120 124 120 124 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009872-Roux1">[35]</xref>
###xml 536 540 520 524 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">RAF1</italic>
###xml 678 682 646 650 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ERK1</italic>
###xml 687 691 655 659 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ERK2</italic>
###xml 947 951 883 887 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009872-Ueda1">[36]</xref>
There are two main pathways through which MAP kinases signal: the classical MAPK pathway and the p38 MAP kinase pathway [35]. The first step in the activation of classical MAPK signalling is ligand binding to a receptor tyrosine kinase. The phosphorylated tyrosine of the target protein is bound by the SH2 domain of GRB2, which also contains an SH3 domain that binds to the proline-rich region of SOS. Once bound by GRB2, SOS catalyses the substitution of GDP to GTP on RAS (down double arrow4.96). GTP-bound RAS activates the MAPKKK, RAF1 (down double arrow2.10), by phosphorylation. RAF1 subsequently phosphorylates the MAPKKs, MEK1/2, which in turn activate the MAP kinases ERK1 and ERK2 (down double arrow1.71). MAPK interacting serine/threonine 2 (MKNK2) is directly activated by ERK, and is itself downregulated (down double arrow3.24). MKNK2 contributes to the basal phosphorylation of eIF4A, which is essential for translation initiation [36]. Downregulation of these core pathway components suggests repression of the basal response to growth factors, an effect that appears to be amplified by upregulation of the Ras inhibitor, NF1 (up dbl arrow1.81) and the ERK1/2 inhibitor, PTPN5, (up dbl arrow1.59).
###end p 64
###begin p 65
###xml 207 208 207 208 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 715 719 656 660 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009872-Roux1">[35]</xref>
###xml 862 863 787 788 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">c</italic>
###xml 863 867 788 792 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009872-Rane1">[37]</xref>
Activation of p38 is mediated by multiple upstream kinases and this pathway plays a key role in the cell's stress response as well as the phosphorylation of multiple target proteins including phospholipase A2 and MAP tau. TAK1 (down double arrow2.42) is an upstream kinase that phosphorylates MAPK kinases 3 and 6 (MEK3, 6), which subsequently phosphorylate p38 (down double arrow5.34). There is strong downregulation of the p38 MAPK signalling pathway, which is strengthened by upregulation of the p38 (and ERK1/2) inhibitor PTPN5 (up dbl arrow1.59). Additionally, the p38 target, MK2 is downregulated (down double arrow1.60), which plays a role in the regulation of mRNA stability and the reorganisation of actin [35]. MK2 activates Hsp27 (down double arrow12.85), which binds to and inactivates the pro-apoptotic molecules caspase-3, caspase-9 and cytochrome c[37].
###end p 65
###begin title 66
###xml 20 28 20 28 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0009872-g005">Figure 5</xref>
Calcium signalling (Figure 5)
###end title 66
###begin title 67
Defects in calcium signalling as a result of CHMP2B mutations.
###end title 67
###begin p 68
###xml 39 40 35 36 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">q</sub>
###xml 66 69 46 49 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">q11</sub>
###xml 305 306 252 253 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 353 354 300 301 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 508 510 439 441 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2+</sup>
###xml 562 564 493 495 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2+</sup>
###xml 625 627 556 558 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2+</sup>
###xml 724 726 655 657 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2+</sup>
Downregulation of the alpha-subunits, Gq (down double arrow) and Gq11 (down double arrow) indicates a decrease in PLCbeta activation, despite upregulation of the cholinergic receptor CHRM3 (up dbl arrow). A decrease in PLCbeta activity would reduce the amount of phosphatidylinositol 4,5-bisphosphate (PIP2) hydrolysed to inositol 1,4,5-triphosphate (IP3) and diacylglycerol (DAG). Combining the decrease in IP3, with downregulation of its receptor, IP3R (down double arrow), would reduce the opening of a Ca2+-release channel on the ER membrane, which allows Ca2+ to exit the ER lumen into the cytosol. SERCA, which pumps Ca2+ out of the cytoplasm into the ER lumen is upregulated, so these findings predict an increased Ca2+ concentration in the ER lumen. Upregulation of NCX1(up dbl arrow) and VDAC3(up dbl arrow), and downregulation of ANT3(down double arrow), predict that mitochondria are increasing the amount of calcium pumped out of the matrix, but decreasing the amount of ATP leaving the organelle. Amplifying the aberrant intracellular calcium levels, in addition to reducing the amount of energy available for cellular processes. (PM = plasma membrane; OMM = outer mitochondrial matrix; IMM = inner mitochondrial matrix).
###end p 68
###begin p 69
###xml 68 73 68 73 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHRM3</italic>
###xml 113 119 102 108 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHMP2B</italic>
###xml 152 153 141 142 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 156 157 145 146 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 218 219 201 202 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">q</sub>
###xml 241 245 220 224 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009872-Cummins1">[38]</xref>
###xml 265 266 244 245 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">q</sub>
###xml 264 266 243 245 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">G<sub>q</sub></italic>
###xml 272 275 251 254 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">q11</sub>
###xml 271 275 250 254 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">G<sub>q11</sub></italic>
###xml 435 440 379 384 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHRM3</italic>
###xml 548 549 489 490 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 585 586 526 527 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 616 617 557 558 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 633 634 574 575 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 647 648 588 589 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 645 649 586 590 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IP<sub>3</sub>R</italic>
###xml 744 745 669 670 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 754 756 679 681 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2+</sup>
###xml 1002 1004 927 929 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2+</sup>
###xml 1013 1018 938 943 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SERCA</italic>
###xml 1104 1108 1018 1022 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009872-Szabadkai1">[39]</xref>
###xml 1354 1358 1252 1256 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">NCX1</italic>
###xml 1417 1422 1304 1309 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VDAC3</italic>
###xml 1656 1661 1532 1537 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SERCA</italic>
###xml 1661 1665 1537 1541 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009872-Szabadkai1">[39]</xref>
###xml 1667 1671 1543 1547 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">NCX1</italic>
###xml 1676 1681 1552 1557 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SERCA</italic>
###xml 1823 1830 1699 1706 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0009872-t005">Table 5</xref>
The G protein coupled receptor, cholinergic receptor, muscarinic 3 (CHRM3), is upregulated (up dbl arrow2.92) in CHMP2B mutant motor neurons. Muscarinic3 (M3) receptors couple to phospholipase Cbeta (PLCbeta) via the Gq class alpha-subunits [38]. However, as both Gq and Gq11 are downregulated (down double arrow3.08 and down double arrow2.51, repectively), this would predict a decrease in PLCbeta activation, despite the increase in CHRM3 transcription. PLCbeta functions by catalysing the hydrolysis of phosphatidylinositol 4,5-bisphosphate (PIP2) to inositol 1,4,5-triphosphate (IP3) and diacylglycerol (DAG). IP3 binds to the IP3 receptor (IP3R, down double arrow1.93), which is located on the ER membrane, resulting in the opening of a IP3-gated Ca2+-release channel, thus allowing calcium to exit the ER lumen and enter the cytoplasm, where it can propagate the signal by activating protein kinase C (PKC). Following depletion of ER stores, calcium is re-accumulated through sarco-endoplasmic Ca2+ ATPase (SERCA, up dbl arrow2.12), which is directly controlled by the ATP supplied by mitochondria [39]. ANT3 catalyses the exchange of ATP for ADP from the mitochondrial matrix through the inner mitochondrial membrane into the inter-membrane space, and is downregulated (down double arrow1.82). Solute carrier family 8, sodium/calcium exchanger 1 (NCX1, up dbl arrow3.21) and voltage-dependent anion channel 3 (VDAC3, up dbl arrow2.93), are located on the inner mitochondrial membrane and outer mitochondrial membrane, respectively, and pump calcium out of the mitochondrial matrix and into the cytoplasm, where it is transported to the ER lumen via SERCA[39]. NCX1 and SERCA were selected for verification by Q-PCR, and were found to be upregulated by 25.75 fold (p<0.0001) and 1.66 fold (p = 0.0044), respectively (Table 5).
###end p 69
###begin p 70
###xml 52 56 52 56 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E2F6</italic>
###xml 75 80 75 80 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDH13</italic>
###xml 246 253 246 253 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0009872-t005">Table 5</xref>
We additionally validated E2F transcription factor (E2F6) and cadherin 13 (CDH13) by Q-PCR. These genes had microarray fold changes of 2.80 and 5.66, respectively, and Q-PCR fold changes of 3.54 (p = 0.0112) and 10.43 (p = 0.0038), respectively (Table 5).
###end p 70
###begin title 71
Cellular pathology of CHMP2B mutations
###end title 71
###begin p 72
###xml 34 40 34 40 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHMP2B</italic>
###xml 133 139 133 139 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHMP2B</italic>
###xml 199 205 199 205 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHMP2B</italic>
###xml 338 347 338 347 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0009872-g006">Figure 6A</xref>
###xml 557 568 557 568 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0009872-g006">Figure 6B&#8211;D</xref>
###xml 665 666 661 662 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 757 765 753 761 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0009872-g007">Figure 7</xref>
###xml 876 877 868 869 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 1137 1146 1129 1138 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0009872-g006">Figure 6E</xref>
###xml 1223 1229 1215 1221 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHMP2B</italic>
###xml 1551 1557 1543 1549 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHMP2B</italic>
###xml 1650 1661 1642 1653 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0009872-g006">Figure 6F&#8211;H</xref>
###xml 1866 1878 1858 1870 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0009872-g006">Figure 6 I&#8211;K</xref>
###xml 2190 2194 2182 2186 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009872-Rubinsztein1">[40]</xref>
###xml 2481 2489 2473 2481 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0009872-g008">Figure 8</xref>
To identify pathogenic effects of CHMP2B mutations, HEK-293 cells were transfected with constructs containing myc-tagged full-length CHMP2B with either wild-type or p.I29V, p.T104N or p.Q206H mutant CHMP2B. 24 hours after transfection, cells expressing wild-type CHMP2B showed a typically diffuse pattern of staining throughout the cell (Figure 6A). Cells expressing mutant CHMP2B isoforms had large cytoplasmic vacuoles that were devoid of lumenal staining for the recombinant protein, such vacuoles were rarely seen in cells expressing wild-type protein (Figure 6B-D). Image analysis showed there were significantly more vacuoles with an area greater than 1microm2 in cells expressing mutant CHMP2B protein compared to wild-type (one way ANOVA: p<0.0001, Figure 7). Additionally, the presence of mutant CHMP2B increased the number of cells with vacuoles greater than 1microm2 in area (Bonferroni post-test, p<0.001), as did serum withdrawal (Bonferroni post-test, p<0.0001). A second phenotype observed in the mutant cells was the presence of vacuoles with an accumulation of CHMP2B mutant protein on the outer membrane, termed halos (Figure 6E). The number of cells with halos in cells expressing the p.T104N isoform of CHMP2B was significantly increased (Bonferroni post-test, p<0.05). When cells were deprived of serum the presence of halos was even more striking in mutant cells. Co-staining with CD63, a tetraspanin that is abundant in late endosomes and lysosomes, revealed an interesting change in staining pattern in cells expressing mutant CHMP2B. In cells expressing WT CHMP2B, CD63 co-localises with small vacuoles within the cytoplasm (Figure 6F-H). In cells expressing mutant CHMP2B, CD63 does not co-localise with the large cytoplasmic vacuoles caused by mutant CHMP2B transfection, but instead is found on the membrane of these aberrant structures (Figure 6 I-K). Immunoblotting of LC3 typically reveals two bands, LC3-I (18kDa) and LC3-II (16kDa). During the formation of autophagosomes, the cytoplasmic form of LC3 (LC3-I) is recruited, where it undergoes site-specific proteolysis and lipidation, generating LC3-II which sequesters to the membrane of the autophagosomes [40]. The level of LC3-II can be used to monitor autophagic activity, as it correlates with the number of autophagosomes. Western blotting for LC3 in COS-7 cells showed a significant increase in LC3-II levels in cells expressing mutant CHMP2B compared to those expressing wild-type protein (Figure 8).
###end p 72
###begin title 73
Overexpression of mutant CHMP2B produces an aberrant phenotype in HEK-293 cells.
###end title 73
###begin p 74
Cells were transfected with vectors encoding recombinant protein c-Myc-CHMP2B with either the wild-type or I29V, T104N or Q206H mutant sequence, and stained with FITC-conjugated antibody to c-Myc. Transfection with wild-type CHMP2B (A) results in generalised cytoplasmic expression, whereas the mutant isoforms I29V (B), T104N (C) and Q206H (D) resulted in cytoplasmic vacuoles of varying size (indicated by arrowheads). Another striking observation was the presence within cells expression mutant CHMP2B of circular CHMP2B accumulations in the cytoplasm, termed halos (E). Cells were doubly stained with antibodies to c-Myc (F & I), as well as CD63 (G & J), and merged to show co-localisation (H & K). CD63 co-localises with the small vacuoles found in cells transfected with WT CHMP2B (F-H). However, CD63 staining does not co-localise with large vacuoles in mutant expressing cells (cells transfected with T104N shown), but are found on the vacuole edge (I-K). Images were taken on a Zeiss LSM 510 confocal microscope, x63 obj. Bar, 10microm.
###end p 74
###begin title 75
Mutant CHMP2B causes large cytoplasmic vacuoles.
###end title 75
###begin p 76
###xml 108 109 104 105 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
Cells expressing 3 different mutant CHMP2B had significantly more vacuoles with an area greater than 1microm2 in than cells expressing wild-type protein (One-way ANOVA p<0.0001, +/-: cells grown in DMEM with FCS, without antibiotic).
###end p 76
###begin title 77
LC3-II levels are increased in cells expressing mutant CHMP2B.
###end title 77
###begin p 78
A representative image of western blotting to LC3 and actin (A), showing increased levels of LC3-II in COS-7 cells expressing mutant CHMP2B protein (lanes 2-4) compared to cells expressing wild-type protein (lane 1). LC3-II levels relative to an actin loading control were measured using densitometry (B), and this showed increased levels of LC3-II in mutant expressing cells compared to WT (mean +/-S.E.M., n = 3) (Mann Whitney p = 0.0242). Average fold changes in LC3-II levels normalised to WT are shown for each of the three mutants (C).
###end p 78
###begin title 79
Discussion
###end title 79
###begin p 80
###xml 47 53 47 53 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHMP2B</italic>
###xml 279 283 279 283 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009872-Rosen1">[41]</xref>
###xml 309 313 309 313 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009872-Andersen1">[42]</xref>
###xml 315 319 315 319 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009872-Jackson1">[43]</xref>
###xml 321 325 321 325 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009872-Jones1">[44]</xref>
###xml 361 367 361 367 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHMP2B</italic>
###xml 946 950 946 950 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009872-Graham1">[45]</xref>
###xml 1028 1034 1028 1034 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHMP2B</italic>
In our cohort, we have identified mutations in CHMP2B in four out of 433 individuals with ALS, giving a frequency of just less than 1%. This is approximately half of the frequency of SOD1 mutations, which have been reported to account for approximately 20% of familial ALS cases [41], and 2% of all ALS cases [42], [43], [44]. Of note, only 1 of our 4 cases of CHMP2B associated ALS/MND had a discernible family history compatible with ALS in a second-degree relative. This supports the hypothesis that some apparently sporadic ALS cases have a genetic component. Evidence from a UK twin study, which examined concordance in both mono- and dizygotic twins (having first excluded probands from families in which dominant inheritance of MND had already been identified), estimated the heritability of ALS to be between 0.38 and 0.85; indicating that genetic factors are likely to make a substantial contribution to the sporadic form of the disease [45]. Although the present study has not been able to document the segregation of CHMP2B in multiple affected members of specific pedigrees in ALS, we believe our results support the body of evidence for the contribution of genetic factors to apparently sporadic ALS.
###end p 80
###begin p 81
###xml 56 60 56 60 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SOD1</italic>
###xml 62 65 62 65 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ANG</italic>
###xml 67 72 67 72 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TDP43</italic>
###xml 74 90 74 90 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VAPB and FUS/TLS</italic>
###xml 311 317 311 317 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHMP2B</italic>
###xml 590 594 590 594 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009872-Borthwick1">[46]</xref>
###xml 705 712 705 712 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FUS/TLS</italic>
###xml 712 716 712 716 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009872-Shaw2">[47]</xref>
###xml 726 732 726 732 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHMP2B</italic>
###xml 868 874 868 874 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHMP2B</italic>
###xml 905 913 <span type="species:ncbi:9606">patients</span>
All 4 cases in this report were negative for changes in SOD1, ANG, TDP43, VAPB and FUS/TLS. Clinically, all four cases presented with a phenotype consistent with a lower motor neuron phenotype of ALS. In this cohort only 40 cases are recorded clinically as having a lower motor neuron predominant phenotype and CHMP2B mutations were found in 4 (10%) of these cases. In our autopsy cohort, 15/123 cases had a LMN phenotype pathologically. Of these 15, three lack any evidence of ubiquitin/TDP43 neuronal inclusion pathology, one in the presence of a mitochondrial transfer RNA gene mutation [46], and another as one of a pair of brothers with MND and colonic neoplasia recently found to have a mutation in FUS/TLS[47]. As such CHMP2B-related ALS is highly over-represented in this LMN predominant clinical subgroup. It is interesting to note that although mutations in CHMP2B were originally identified in patients with FTD, none of the four cases we identified had clinically apparent cognitive changes and there were no noteworthy pathological changes in the hippocampus.
###end p 81
###begin p 82
###xml 170 176 170 176 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHMP2B</italic>
###xml 176 180 176 180 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009872-Blair1">[48]</xref>
###xml 308 314 308 314 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TARDBP</italic>
###xml 349 353 349 353 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009872-Gijselinck1">[49]</xref>
###xml 355 359 355 359 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009872-Guerreiro1">[50]</xref>
###xml 386 390 386 390 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SOD1</italic>
###xml 452 456 452 456 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009872-vanEs1">[51]</xref>
A previous report of 166 familial and 372 sporadic "classical" ALS cases of predominantly Anglo-Celtic origin from Australia and London found no evidence of mutations in CHMP2B[48]. However, population differences in other ALS pathogenic mutations have been previously reported as exemplified by the lack of TARDBP mutations in some populations and [49], [50] the very low frequency of SOD1 mutations reported in some countries such as the Netherlands [51].
###end p 82
###begin p 83
###xml 546 549 546 549 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009872-Parkinson1">[3]</xref>
###xml 551 554 551 554 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009872-Skibinski1">[4]</xref>
###xml 556 560 556 560 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009872-Blair1">[48]</xref>
###xml 562 566 562 566 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009872-vanderZee1">[52]</xref>
###xml 790 794 790 794 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009872-Cannon1">[53]</xref>
###xml 893 896 893 896 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009872-Parkinson1">[3]</xref>
###xml 898 901 898 901 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009872-Skibinski1">[4]</xref>
###xml 903 907 903 907 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009872-Blair1">[48]</xref>
###xml 909 913 909 913 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009872-vanderZee1">[52]</xref>
###xml 1030 1034 1030 1034 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009872-Guerreiro2">[54]</xref>
In silico analysis of the identified amino acid substitutions predicts that the p.I29V and p.Q206H mutations decrease protein stability (). The native threonine of the p.T104N change is predicted to be a site of phosphorylation (), thus substitution of threonine with asparagine is predicted to affect protein activity. We did not identify any of the described codon changes in our 500 controls, whilst previous studies have sequenced 1495 samples for exon 3 and 2035 samples for exon 6, without identifying the p.T104N and p.Q206H substitutions [3], [4], [48], [52]. We therefore propose that these changes are not rare benign polymorphisms, but are associated with disease. Although the p.I29V substitution has been reported in a single control sample, as well as in a familial FTLD case [53], screening of our 500 controls, 640 previously screened controls, 708 ALS cases and 546 FTD cases [3], [4], [48], [52] has failed to detect this change. Therefore, whilst it is recognised that not all missense mutations are pathogenic [54], the clinical, neuropathological and cellular phenotype common to all 3 CHMP2B mutations, and which is distinct from controls, supports the proposal that all 3 nucleotide substitutions described in this report are associated with a lower motor neuron dominant-ALS. The c.-151C>A polymorphism is predicted to alter the binding site for an unknown transcription factor (). However, there is no significant difference in frequency between subjects and controls (Chi Square p = 0.9), and therefore this change is likely to represent a non-functional polymorphism.
###end p 83
###begin p 84
###xml 621 627 609 615 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHMP2B</italic>
###xml 749 755 737 743 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHMP2B</italic>
###xml 477 485 <span type="species:ncbi:9606">patients</span>
The pathology is rather stereotypical and, whilst firmly within the ALS/MND spectrum, appears to represent a rather distinctive lower motor neuron variant. The inclusion morphology does not correspond to the predominant pattern seen in classical ALS/MND, where skein inclusions predominate in approximately90% of cases, so that the absence of classical skeins in this group is distinctive. Bunina bodies are found in up to 75-80% of ALS/MND cases, and their absence in these 4 patients is again suggestive of an atypical group. While these features are not sufficiently distinctive to allow a morphological prediction of CHMP2B-related MND, our results indicate that a predominance of compact inclusions in a PMA case may warrant examination of the CHMP2B gene.
###end p 84
###begin p 85
###xml 73 79 73 79 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHMP2B</italic>
###xml 291 295 291 295 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SOD1</italic>
###xml 354 360 354 360 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHMP2B</italic>
###xml 530 535 530 535 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KIF1A</italic>
###xml 537 542 537 542 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KIF1C</italic>
###xml 544 557 544 557 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KIF5C DYNLRB1</italic>
###xml 559 565 559 565 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">DYNLL2</italic>
###xml 570 577 570 577 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">DYNC1H1</italic>
###xml 702 706 702 706 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009872-DeVos1">[55]</xref>
###xml 765 770 765 770 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MAP1S</italic>
###xml 772 776 772 776 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MAP4</italic>
###xml 776 780 776 780 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009872-Halpain1">[25]</xref>
###xml 1033 1037 1033 1037 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009872-Strey1">[56]</xref>
###xml 1198 1202 1198 1202 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009872-Gonatas1">[57]</xref>
###xml 1289 1293 1289 1293 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009872-Ferraiuolo1">[19]</xref>
###xml 1295 1299 1295 1299 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ATG1</italic>
###xml 1369 1374 1369 1374 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ATG17</italic>
###xml 1379 1384 1379 1384 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ATG13</italic>
###xml 1523 1527 1523 1527 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009872-Cheong1">[30]</xref>
###xml 1810 1814 1810 1814 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009872-Sarkar1">[58]</xref>
###xml 2129 2133 2129 2133 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009872-Sarkar1">[58]</xref>
###xml 2461 2465 2461 2465 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009872-Raught1">[59]</xref>
###xml 3018 3023 3018 3023 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HSP27</italic>
###xml 3124 3129 3124 3129 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MKNK2</italic>
###xml 3134 3137 3134 3137 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">AKT</italic>
###xml 3330 3334 3330 3334 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009872-Corcelle1">[60]</xref>
###xml 3401 3407 3401 3407 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHMP2B</italic>
###xml 3508 3512 3508 3512 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009872-Lee1">[12]</xref>
###xml 3542 3543 3538 3539 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">q</sub>
###xml 3536 3543 3536 3539 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">G&#945;<sub>q</sub></italic>
###xml 3554 3556 3546 3548 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">11</sub>
###xml 3548 3556 3544 3548 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">G&#945;<sub>11</sub></italic>
###xml 3583 3584 3575 3576 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 3688 3689 3677 3678 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 3778 3783 3767 3772 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SERCA</italic>
###xml 3827 3831 3816 3820 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">NCX1</italic>
###xml 3836 3841 3825 3830 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VDAC3</italic>
###xml 3978 3980 3967 3969 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2+</sup>
###xml 4013 4015 4002 4004 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2+</sup>
###xml 4060 4062 4049 4051 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2+</sup>
###xml 4208 4212 4197 4201 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009872-Paschen1">[61]</xref>
###xml 1028 1032 <span type="species:ncbi:10090">mice</span>
###xml 1284 1288 <span type="species:ncbi:10090">mice</span>
Microarray analysis of the gene expression profile of motor neurons with CHMP2B mutations compared to neurologically normal control samples reveals some interesting changes to genes involved in key cellular processes, many of which are distinct to those shown by motor neurons isolated from SOD1-related ALS cases (Kirby et al, manuscript under review). CHMP2B cases show downregulation in multiple transcripts encoding proteins involved in the transport of cargoes along microtubules, suggesting impairments in axonal transport (KIF1A, KIF1C, KIF5C DYNLRB1, DYNLL2 and DYNC1H1), a phenomenon that has been well documented in multiple neurodegenerative diseases, including a SOD1-mediated model of ALS [55]. Interestingly, the dysregulation of microtubule proteins MAP1S, MAP4[25] and stathmin, predicts loss of cell structure and transport network. It has been shown that stathmin overexpression in HeLa cells leads to Golgi fragmentation and microtubule disassembly, which are the same events observed in transgenic G93A SOD1 mice [56]. Stathmin overexpression and Golgi fragmentation seem to be early events in the neurodegenerative cascade characteristic of ALS and other neurological diseases [57], and has been confirmed by transcriptional analysis in pre-symptomatic G93A SOD1 mice [19]. ATG1 (3.48 fold) is strongly downregulated, and is part of a complex with ATG17 and ATG13. This complex is required for the formation of vesicles at the phagophore assembly site, which is a crucial step for autophagy initiation [30]. A decrease in autophagy initiation may result in the accumulation of cytosolic aggregates, which could potentially contribute to motor neuron injury. It is of great interest that a recent study in a fly model of Huntington's disease combined the treatment of rapamycin and lithium [58]. Inhibition of mTOR by rapamycin and the induction of mTOR-independent autophagy by lithium resulted in an increase in autophagy in both an mTOR-dependent and mTOR-independent manner, enhanced the clearance of protein aggregates and provided greater protection than single treatment with either of these molecules [58]. In addition, our results predict a global repression of protein translation within the cell due to the downregulation of multiple translation initiation factors. Translation initiation is a critical checkpoint and step of the translation process, and is the stage at which control of mRNA translation is most strongly exerted [59]. This may be an effect of end-stage disease, where the cell is attempting to survive at the expense of general protein synthesis, or it may be in response to a compromised ER trying to prevent accumulation of misfolded proteins. The classical MAPK cascade and the p38 signalling pathway both show downregulation of multiple components, alongside upregulation of inhibitors of signal amplification. This would predict that the cell is unable to respond normally to stimulation from growth factors, cytokines or environmental stresses. Downregulation of HSP27, which plays a role in neuronal survival, in conjunction with the altered transcriptional levels of MKNK2 and AKT suggests that the motor neurons are in a state that predisposes to apoptosis. Interestingly, pharmacological abrogation of p38 by SB203580, resulted in the accumulation of large autolysosomes [60]. Downregulation of p38 is therefore potentially very important as CHMP2B functions in degradation and recycling pathways, and mutations result in autophagosome accumulation [12]. The downregulation of Galphaq and Galpha11 suggests a reduction in IP3 levels as a result of decreased PLCbeta activity, and this in conjunction with the downregulation of IP3R, predicts a reduction in calcium release from the ER. In addition, the upregulation of SERCA and the mitochondrial calcium transporters NCX1 and VDAC3, may result in excess calcium being transported out of the mitochondria and into the ER lumen, having the net effect of an increased [Ca2+] in the ER lumen and reduced [Ca2+] in the mitochondria. Tight control of ER Ca2+ stores is crucial for cell survival, and it has been previously demonstrated that increased ER calcium levels trigger ceramide-induced apoptosis [61].
###end p 85
###begin p 86
###xml 117 123 117 123 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHMP2B</italic>
###xml 190 202 190 202 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0009872-g006">Figure 6 B&#8211;D</xref>
###xml 467 479 467 479 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0009872-g006">Figure 6 I&#8211;J</xref>
###xml 622 626 622 626 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009872-Pols1">[62]</xref>
###xml 809 821 809 821 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0009872-g006">Figure 6 F&#8211;H</xref>
###xml 937 949 937 949 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0009872-g006">Figure 6 I&#8211;K</xref>
###xml 990 996 990 996 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHMP2B</italic>
###xml 1268 1274 1268 1274 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHMP2B</italic>
###xml 1424 1428 1424 1428 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009872-vanderZee1">[52]</xref>
###xml 1025 1032 <span type="species:ncbi:9606">patient</span>
We have demonstrated in a HEK-293 cellular model that transfection of constructs carrying p.I29V, p.T104N or p.Q206H CHMP2B mutations results in the formation of large cytoplasmic vacuoles (Figure 6 B-D). Induction of autophagy resulted in an increase in the number of vacuoles, providing further evidence that functional CHMP2B is required for the degradation of cytoplasmic components. These mutations caused aberrant CD63 accumulation within the cytosol (p.T104N: Figure 6 I-J; p.I29V & p.Q206H: data not shown). CD63 is found abundantly in lysosomes, and its trafficking and cellular distribution is tightly regulated [62]. The small vacuoles found in cells expressing WT CHMP2B co-localised with large areas of CD63 staining - displaying the normal physiological fusion of late endosomes with lysosomes (Figure 6 F-H). In contrast, cells expressing mutant CHMP2B often showed CD63 immunostaining on the membranes of large vacuoles (Figure 6 I-K). These data indicate that the missense CHMP2B mutations identified in our patient cohort disrupt the fusion of the lysosome with the large cytoplasmic vacuoles, suggesting that mutant CHMP2B is altering the dynamics of this fundamental process. This hypothesis is further supported by the transfection of FTD-related CHMP2B truncating mutations in neuroblastoma cell lines, which led to the formation of large vesicles, with a morphology in keeping with aberrant endosomes [52].
###end p 86
###begin p 87
###xml 401 405 401 405 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009872-Hara1">[63]</xref>
###xml 407 411 407 411 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009872-Komatsu1">[64]</xref>
###xml 457 463 457 463 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHMP2B</italic>
###xml 592 599 592 599 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Intron5</sup>
###xml 783 787 783 787 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009872-Lee1">[12]</xref>
###xml 827 834 827 834 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Intron5</sup>
###xml 845 852 845 848 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#916;10</sup>
###xml 973 977 969 973 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009872-Filimonenko1">[13]</xref>
###xml 1151 1155 1147 1151 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009872-Lee2">[65]</xref>
###xml 1157 1161 1153 1157 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009872-Lee3">[66]</xref>
###xml 1467 1471 1463 1467 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0009872-Klionsky1">[67]</xref>
###xml 1748 1754 1744 1750 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHMP2B</italic>
###xml 1968 1976 1964 1972 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0009872-g002">Figure 2</xref>
###xml 2175 2181 2171 2177 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHMP2B</italic>
###xml 2275 2281 2271 2277 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHMP2B</italic>
###xml 142 147 <span type="species:ncbi:4932">yeast</span>
###xml 151 157 <span type="species:ncbi:9606">humans</span>
###xml 189 193 <span type="species:ncbi:10090">mice</span>
###xml 2044 2052 <span type="species:ncbi:9606">patients</span>
The MVB pathway has an essential role in the delivery of ubiquitinated proteins to the lysosome for degradation, and is highly conserved from yeast to humans. It has been demonstrated that mice deficient in genes essential for autophagy are unable to effectively clear cellular debris, leading to the accumulation of polyubiquitinated proteins within inclusion bodies and subsequent neurodegeneration [63], [64]. Additionally, there is strong evidence that CHMP2B mutations result in neuronal death; dendritic retraction and cell death seen in cortical neuron cultures transfected with CHMP2BIntron5 is a result of the failure of the aberrant protein to dissociate from the other subunits of the ESCRTIII prior to the next round of sorting, a step critical for the formation of MVBs [12]. Transfection of HeLa cells with CHMP2BIntron5 and CHMP2BDelta10 results in increased levels of ubiquitin and p62 and inhibition of protein degradation through the process of autophagy [13]. Inhibiting autophagy induction in cells transfected with mutant CHMP2B resulted in delayed neuronal loss, further implicating autophagy in the process of neurodegeneration [65], [66]. In the present study, we have demonstrated that LC3-II levels are significantly increased in cells expressing mutant CHMP2B. Autophagosomes sequester the target organelle/protein and fuse with lysosomes, where the contents - and the LC3-II present on the luminal side of the autophagosome - are degraded [67]. The half-life of LC3-II is short due to the balance of autophagosome synthesis and degradation; thus the increased levels of LC3-II in mutant-expressing cells is indicative of an alteration in the degradation of cargo by the autophagic pathway. We therefore propose that the CHMP2B mutations we have identified may contribute to motor neuron injury through dysfunction of the autophagic clearance of cellular proteins, and the formation of ubiquitin positive inclusions with compact morphology (Figure 2). Further mutation screening now needs to take place in cohorts of patients, particularly those with a lower motor neuron disease phenotype, and from different geographical areas. Identification of CHMP2B mutations showing segregation with familial disease would establish conclusively the role of CHMP2B as a causative gene in ALS.
###end p 87
###begin title 88
Supporting Information
###end title 88
###begin p 89
The 891 genes downregulated and 561 genes upregulated in motor neurons with CHMP2B mutations, grouped into biological processes.
###end p 89
###begin p 90
(0.23 MB XLS)
###end p 90
###begin p 91
Click here for additional data file.
###end p 91
###begin p 92
###xml 30 35 <span type="species:ncbi:9606">human</span>
Multiple protein alignment of human CHMP2B, mutant isoforms and orthologues. Amino acids are shaded based on their properties; polar amino acids are bright, whereas non-polar residues are darker. Missense mutations identified in the MND cohort (p.I29V, p.T104N and p.Q206H) are labelled *.
###end p 92
###begin p 93
(5.73 MB TIF)
###end p 93
###begin p 94
Click here for additional data file.
###end p 94
###begin p 95
###xml 280 288 <span type="species:ncbi:9606">patients</span>
We thank Hazel Holden, Catherine Gelsthorpe and Lynne Baxter for technical assistance; Dr Roy Milner for cell and molecular biology support. We also thank the Newcastle Brain Tissue Resource and NeuroResource, UCL for additional control material. We are extremely grateful to the patients with ALS and their families for the generous gift to research of blood samples to the MND DNA banks and CNS tissue donation to the Sheffield Brain Tissue Bank.
###end p 95
###begin title 96
References
###end title 96
###begin article-title 97
Molecular and cellular pathways of neurodegeneration in motor neurone disease.
###end article-title 97
###begin article-title 98
Genetics of amyotrophic lateral sclerosis.
###end article-title 98
###begin article-title 99
ALS phenotypes with mutations in CHMP2B (charged multivesicular body protein 2B).
###end article-title 99
###begin article-title 100
Mutations in the endosomal ESCRTIII-complex subunit CHMP2B in frontotemporal dementia.
###end article-title 100
###begin article-title 101
Escrt-III: an endosome-associated heterooligomeric protein complex required for mvb sorting.
###end article-title 101
###begin article-title 102
The Vps4p AAA ATPase regulates membrane association of a Vps protein complex required for normal endosome function.
###end article-title 102
###begin article-title 103
Ubiquitin-dependent sorting into the multivesicular body pathway requires the function of a conserved endosomal protein sorting complex, ESCRT-I.
###end article-title 103
###begin article-title 104
###xml 0 4 <span type="species:ncbi:10090">Mice</span>
Mice deficient in the Rab5 guanine nucleotide exchange factor ALS2/alsin exhibit age-dependent neurological deficits and altered endosome trafficking.
###end article-title 104
###begin article-title 105
Molecular and cellular function of ALS2/alsin: implication of membrane dynamics in neuronal development and degeneration.
###end article-title 105
###begin article-title 106
The Rab5 activator ALS2/alsin acts as a novel Rac1 effector through Rac1-activated endocytosis.
###end article-title 106
###begin article-title 107
A mutation in the vesicle-trafficking protein VAPB causes late-onset spinal muscular atrophy and amyotrophic lateral sclerosis.
###end article-title 107
###begin article-title 108
ESCRT-III dysfunction causes autophagosome accumulation and neurodegeneration.
###end article-title 108
###begin article-title 109
Functional multivesicular bodies are required for autophagic clearance of protein aggregates associated with neurodegenerative disease.
###end article-title 109
###begin article-title 110
Autophagy and neurodegeneration: when the cleaning crew goes on strike.
###end article-title 110
###begin article-title 111
Molecular Neuropathology of TDP-43 Proteinopathies.
###end article-title 111
###begin article-title 112
TDP-43 is a component of ubiquitin-positive tau-negative inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis.
###end article-title 112
###begin article-title 113
Mutations in progranulin cause tau-negative frontotemporal dementia linked to chromosome 17.
###end article-title 113
###begin article-title 114
Screening of the transcriptional regulatory regions of vascular endothelial growth factor receptor 2 (VEGFR2) in amyotrophic lateral sclerosis.
###end article-title 114
###begin article-title 115
###xml 131 136 <span type="species:ncbi:10090">mouse</span>
Microarray analysis of the cellular pathways involved in the adaptation to and progression of motor neuron injury in the SOD1 G93A mouse model of familial ALS.
###end article-title 115
###begin article-title 116
Amplified RNA synthesized from limited quantities of heterogeneous cDNA.
###end article-title 116
###begin article-title 117
DAVID: Database for Annotation, Visualization, and Integrated Discovery.
###end article-title 117
###begin article-title 118
Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.
###end article-title 118
###begin article-title 119
Corticospinal tract degeneration in the progressive muscular atrophy variant of ALS.
###end article-title 119
###begin article-title 120
Pathological TDP-43 distinguishes sporadic amyotrophic lateral sclerosis from amyotrophic lateral sclerosis with SOD1 mutations.
###end article-title 120
###begin article-title 121
The MAP1 family of microtubule-associated proteins.
###end article-title 121
###begin article-title 122
###xml 11 16 <span type="species:ncbi:4932">yeast</span>
Use1p is a yeast SNARE protein required for retrograde traffic to the ER.
###end article-title 122
###begin article-title 123
Upstream and downstream of mTOR.
###end article-title 123
###begin article-title 124
Phosphatidic acid-mediated mitogenic activation of mTOR signaling.
###end article-title 124
###begin article-title 125
GbetaL, a positive regulator of the rapamycin-sensitive pathway required for the nutrient-sensitive interaction between raptor and mTOR.
###end article-title 125
###begin article-title 126
###xml 149 173 <span type="species:ncbi:4932">Saccharomyces cerevisiae</span>
The Atg1 kinase complex is involved in the regulation of protein recruitment to initiate sequestering vesicle formation for nonspecific autophagy in Saccharomyces cerevisiae.
###end article-title 126
###begin article-title 127
mTOR and S6K1 mediate assembly of the translation preinitiation complex through dynamic protein interchange and ordered phosphorylation events.
###end article-title 127
###begin article-title 128
Changes in ribosomal binding activity of eIF3 correlate with increased translation rates during activation of T lymphocytes.
###end article-title 128
###begin article-title 129
Interferon-gamma engages the p70 S6 kinase to regulate phosphorylation of the 40S S6 ribosomal protein.
###end article-title 129
###begin article-title 130
The mTOR/PI3K and MAPK pathways converge on eIF4B to control its phosphorylation and activity.
###end article-title 130
###begin article-title 131
ERK and p38 MAPK-activated protein kinases: a family of protein kinases with diverse biological functions.
###end article-title 131
###begin article-title 132
Mnk2 and Mnk1 are essential for constitutive and inducible phosphorylation of eukaryotic initiation factor 4E but not for cell growth or development.
###end article-title 132
###begin article-title 133
Heat shock protein 27 controls apoptosis by regulating Akt activation.
###end article-title 133
###begin article-title 134
Antisense co-suppression of G(alpha)(q) and G(alpha)(11) demonstrates that both isoforms mediate M(3)-receptor-activated Ca(2+) signalling in intact epithelial cells.
###end article-title 134
###begin article-title 135
Mitochondria: the hub of cellular Ca2+ signaling.
###end article-title 135
###begin article-title 136
In search of an "autophagomometer".
###end article-title 136
###begin article-title 137
Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis.
###end article-title 137
###begin article-title 138
Amyotrophic lateral sclerosis associated with homozygosity for an Asp90Ala mutation in CuZn-superoxide dismutase.
###end article-title 138
###begin article-title 139
Copper/zinc superoxide dismutase 1 and sporadic amyotrophic lateral sclerosis: analysis of 155 cases and identification of a novel insertion mutation.
###end article-title 139
###begin article-title 140
###xml 91 98 <span type="species:ncbi:9606">patient</span>
Identification of a novel exon 4 SOD1 mutation in a sporadic amyotrophic lateral sclerosis patient.
###end article-title 140
###begin article-title 141
British motor neuron disease twin study.
###end article-title 141
###begin article-title 142
###xml 26 33 <span type="species:ncbi:9606">patient</span>
Motor neuron disease in a patient with a mitochondrial tRNAIle mutation.
###end article-title 142
###begin article-title 143
Lower motor neuron degeneration and familial predisposition to colonic neoplasia in two adult siblings.
###end article-title 143
###begin article-title 144
CHMP2B mutations are not a common cause of familial or sporadic amyotrophic lateral sclerosis.
###end article-title 144
###begin article-title 145
Neuronal inclusion protein TDP-43 has no primary genetic role in FTD and ALS.
###end article-title 145
###begin article-title 146
TDP-43 is not a common cause of sporadic amyotrophic lateral sclerosis.
###end article-title 146
###begin article-title 147
Large scale SOD1 mutation screening provides evidence for genetic heterogeneity in amyotrophic lateral sclerosis.
###end article-title 147
###begin article-title 148
CHMP2B C-truncating mutations in frontotemporal lobar degeneration are associated with an aberrant endosomal phenotype in vitro.
###end article-title 148
###begin article-title 149
CHMP2B mutations are not a common cause of frontotemporal lobar degeneration.
###end article-title 149
###begin article-title 150
A thorough assessment of benign genetic variability in GRN and MAPT.
###end article-title 150
###begin article-title 151
Role of axonal transport in neurodegenerative diseases.
###end article-title 151
###begin article-title 152
###xml 140 145 <span type="species:ncbi:10090">mouse</span>
Dysregulation of stathmin, a microtubule-destabilizing protein, and up-regulation of Hsp25, Hsp27, and the antioxidant peroxiredoxin 6 in a mouse model of familial amyotrophic lateral sclerosis.
###end article-title 152
###begin article-title 153
Fragmentation of the Golgi apparatus in neurodegenerative diseases and cell death.
###end article-title 153
###begin article-title 154
A rational mechanism for combination treatment of Huntington's disease using lithium and rapamycin.
###end article-title 154
###begin article-title 155
Phosphorylation of eucaryotic translation initiation factor 4B Ser422 is modulated by S6 kinases.
###end article-title 155
###begin article-title 156
Control of the autophagy maturation step by the MAPK ERK and p38: lessons from environmental carcinogens.
###end article-title 156
###begin article-title 157
Endoplasmic reticulum stress response and neurodegeneration.
###end article-title 157
###begin article-title 158
Trafficking and function of the tetraspanin CD63.
###end article-title 158
###begin article-title 159
###xml 83 87 <span type="species:ncbi:10090">mice</span>
Suppression of basal autophagy in neural cells causes neurodegenerative disease in mice.
###end article-title 159
###begin article-title 160
###xml 76 80 <span type="species:ncbi:10090">mice</span>
Loss of autophagy in the central nervous system causes neurodegeneration in mice.
###end article-title 160
###begin article-title 161
Inhibition of autophagy induction delays neuronal cell loss caused by dysfunctional ESCRT-III in frontotemporal dementia.
###end article-title 161
###begin article-title 162
Autophagy defects contribute to neurodegeneration induced by dysfunctional ESCRT-III.
###end article-title 162
###begin article-title 163
Guidelines for the use and interpretation of assays for monitoring autophagy in higher eukaryotes.
###end article-title 163
###begin p 164
###xml 0 21 0 21 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Competing Interests: </bold>
Competing Interests: The authors have declared that no competing interests exist.
###end p 164
###begin p 165
###xml 0 9 0 9 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Funding: </bold>
Funding: This work was funded by the Wellcome Trust (grant number 069388/Z/02/Z) (). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
###end p 165

